The earnings call reflects a company undergoing a significant strategic pivot with promising long-term potential. While the strategic changes and R&D advancements show promise, the company faces short-term challenges, including a substantial revenue decline and expected disruptions due to restructuring. The sentiment balances between optimism for future growth and the current financial hurdles.

Company Guidance -

Q3 2025

During the Allurion Second Quarter Earnings Conference Call, several key metrics and strategic initiatives were discussed. The company reported a revenue of $3.4 million for the second quarter of 2025, a significant decrease from $11.8 million in the same period of 2024, primarily due to distributor transitions and reduced sales in certain markets. Operating expenses decreased by 48% year-over-year, leading to a 26% improvement in operating loss. Allurion's new strategic direction focuses on combining its Allurion Program with low-dose GLP-1 therapy to address adherence challenges and promote metabolically healthy weight loss. This pivot resulted in a 20% growth in comprehensive obesity management program accounts compared to the first quarter of 2025. The company submitted the fourth module of its PMA to the FDA, with positive results from the AUDACITY Study highlighting a 4.34% mean difference in weight loss between treatment and control groups at 48 weeks. Allurion's cash and cash equivalents stood at $12.7 million as of June 30, 2025, with plans to further align operating expenses with its new strategic direction.

Successful Strategic Pivot

Allurion has shifted its focus towards metabolically healthy weight loss, combining their Allurion Program with low-dose GLP-1 therapy, which has resulted in a 20% growth in high-performing accounts.

R&D and Clinical Pipeline Advances

Allurion has signed a term sheet with a strategic partner to expand manufacturing capabilities and explore the development of a novel GLP-1 drug-eluting intragastric balloon. They have also submitted the fourth and final module of their PMA submission to the FDA, strengthening their data with additional analyses.

Reduction in Operating Expenses

Operating expenses for the second quarter decreased by 48% compared to the prior year, leading to a 26% improvement in operating loss.

Allurion Technologies (ALUR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALUR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-1.70 / -	-3.5	―	―	―
Aug 13, 2025	2025 (Q2)	-0.89 / -2.37	-1.25	-89.20% (-1.12)	―
May 14, 2025	2025 (Q1)	-1.57 / 1.46	2.75	-47.02% (-1.29)	―
Mar 26, 2025	2024 (Q4)	-5.70 / -7.95	-10	20.50% (+2.05)	―
Nov 13, 2024	2024 (Q3)	-4.56 / -3.50	-13.408	73.90% (+9.91)	―
Aug 13, 2024	2024 (Q2)	-6.00 / -1.25	-73.968	98.31% (+72.72)	―
May 14, 2024	2024 (Q1)	-7.00 / 2.75	-10.8	125.46% (+13.55)	―
Mar 21, 2024	2023 (Q4)	-12.70 / -10.00	0.32	-3225.00% (-10.32)	―
Nov 13, 2023	2023 (Q3)	- / -13.41	1.962	-783.38% (-15.37)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALUR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$2.58	$2.54	-1.55%
May 14, 2025	$2.36	$2.92	+23.73%
Mar 26, 2025	$3.11	$3.12	+0.32%
Nov 13, 2024	$17.76	$13.08	-26.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allurion Technologies (ALUR) report earnings?

Allurion Technologies (ALUR) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).

What is Allurion Technologies (ALUR) earnings time?

Allurion Technologies (ALUR) earnings time is at Nov 17, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALUR EPS forecast?

ALUR EPS forecast for the fiscal quarter 2025 (Q3) is -1.7.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing